Antipsychotic drugs, often known as neuroleptics or tranquilizers, are a kind of drug that is mostly used to treat schizophrenia or bipolar illness. They are used to treat psychosis, which includes hallucinations, delusions, and paranoid thoughts, among other things. Antipsychotic drugs are useful for treating psychosis in a short period of time. These drugs inhibit dopamine receptors in the brain’s dopaminergic pathways, suppressing the action of dopamine, which is connected directly to psychotic episodes. As the incidence of mental disease has increased, so has the use of antipsychotics. According to the National Alliance of Mental Illness, one in every five individuals suffers from mental illness, accounting for 18.5 % of the overall population suffering from mental problems. Long-term usage of these medicines, on the other hand, may cause adverse effects such as metabolic syndrome and involuntary movement disorder, eventually resulting in an increase in death in the elderly population having dementia.
Increased incidence of mental illness is expected to drive the global antipsychotic drug market growth over the forecast period.
Schizophrenia is the leading cause of psychosis worldwide, and individuals with the condition are more prone to develop physical and mental disorders. According to the World Health Organization, in 2016, around 21 million people in the world were diagnosed with schizophrenia. According to the WHO, one in every two individuals suffering from schizophrenia does not get adequate treatment. This offers an attractive opportunity for global antipsychotic drugs market players to produce cost-effective treatments for the treatment of this condition. Moreover, according to the National Alliance of Medical Illness in 2017, around 1.1 % of the adult population in the U.S. have schizophrenia, while 2.6 % of the country’s population has bipolar disorder. In a particular year, one in every five individuals, or around 43.8 million people, or 18.5 % of the entire population in the U.S., suffers from some form of mental illness. The rising frequency and incidence of neurological diseases are driving the global antipsychotic drug market growth over the forecast period.
Antipsychotic Drug Market Taxonomy:
On the basis of drug type, the global anti-psychotic drugs market is segmented into:
- First-generation Drugs (Standard / Typical Antipsychotic Agents)
- Thorazine (Chlorpromazine HCl)
- Serentil (Mesoridazine Besylate)
- Mellaril (Thioridazine HCl)
- Haldol (Haloperidol)
- Loxitane (Loxapine Succinate)
- Trilafon (Perphenazine)
- Navane (Thiothixene)
- Sordinol (Clopenthixol)
- Second-generation Drugs (Atypical Antipsychotic Agents)
- Zyprexa (Olanzapine)
- Geodon (Ziprasidone)
- Seroquel (Quetiapine)
- Risperdal (Risperidone)
- Clozaril (Clozapine)
- Invega (Paliperidone)
- Asendin (Amoxapine)
- Latuda (Lurasidone)
- Third-generation Drugs
- Abilify (Aripiprazole)
On the basis of application, the global anti-psychotic drugs market is segmented into:
- Bipolar Disorder
- Unipolar Depression
On the basis of distribution channel, the global anti-psychotic drugs market is segmented into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
North America is expected to account for the largest share in the global antipsychotic drug market due to the growing number of people suffering from mental illnesses.
Geographically, the global antipsychotic drugs market is divided into Europe, North America, Asia Pacific, Latin America, Africa, and the Middle East. North America has the highest market share in the global antipsychotic drugs market, owing to an increase in the incidence of psychosis among the youth population as well as a rising incidence of schizophrenia among the elderly population. According to the National Academy of Mental Illness sociological statistics from 2017, around 70% of youth in the juvenile justice system in the U.S. have at least one mental health problem, with around 20% having a severe mental problem. Due to government attempts to enhance treatment for a growing number of individuals suffering from mental illness, Asia Pacific is expected to witness substantial growth in the global antipsychotic drugs market over the forecast period. According to the World Health Organization (WHO), Pilot Programs in India, Pakistan, and Iran have demonstrated suitability in delivering healthcare to persons with mental health disorders, such as the supply of appropriate medicines and awareness programs to reduce stigma and discrimination associated with mental illness.
Increased drug abuse and the prevalence of drug addiction are inadvertently driving the global antipsychotic drugs market growth over the forecast period.
Rising incidence of schizophrenia and psychotic illnesses is a significant driver of the global antipsychotic drug market. Several additional causes, such as the rising prevalence of drug abuse, overprescribing of psychotic medications, and addictions to antipsychotic drugs, also contribute to the global antipsychotic drugs market growth over the forecast period. According to the National Survey on Drug Use and Health (NSDUH), around 13.2 5 of the U.S. population (around 4 million persons) was using an illegal drug or abused a psychotherapeutic drug in 2012. However, the recent patent expiration of key brands has had an adverse impact on the global antipsychotic drugs market growth over the forecast period. Furthermore, the adverse effects of antipsychotics, which cause insomnia, tardive dyskinesia, and a variety of other problems, are limiting the global antipsychotic drugs market growth over the forecast period.
Major players are concentrating on the development of new and innovative therapeutic drugs in order to improve their position in the global antipsychotic drugs market.
Some of the major players contributing to the global antipsychotic drugs market include Bristol- Myers Squibb, Eli Lily and Co., GlaxoSmithKline, AstraZeneca, Allergen, Johnson & Johnson, and Pfizer, Inc. These players are active in the development of new medications for the treatment of psychotic illnesses with fewer adverse effects in order to boost the demand for the product in the market. Otsuka Pharmaceuticals obtained the U.S. Food and Drug Administration (FDA) approval in November 2017 for Abilify MyCite, the first antipsychotic medication therapy, which is infused with a computerized ingestion tracking system and is intended to treat Schizophrenia and acute bipolar disorder attacks.
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Global Antipsychotic Drugs Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Antipsychotic Drugs Industry Impact
Chapter 2 Global Antipsychotic Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Antipsychotic Drugs (Volume and Value) by Type
2.3 Global Antipsychotic Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Antipsychotic Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Antipsychotic Drugs Market Analysis
Chapter 6 East Asia Antipsychotic Drugs Market Analysis
Chapter 7 Europe Antipsychotic Drugs Market Analysis
Chapter 8 South Asia Antipsychotic Drugs Market Analysis
Chapter 9 Southeast Asia Antipsychotic Drugs Market Analysis
Chapter 10 Middle East Antipsychotic Drugs Market Analysis
Chapter 11 Africa Antipsychotic Drugs Market Analysis
Chapter 12 Oceania Antipsychotic Drugs Market Analysis
Chapter 13 South America Antipsychotic Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Antipsychotic Drugs Business
Chapter 15 Global Antipsychotic Drugs Market Forecast (2021-2027)
Chapter 16 Conclusions
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027